keyword
MENU ▼
Read by QxMD icon Read
search

EBMT

keyword
https://www.readbyqxmd.com/read/28103944/a-comparison-between-allogeneic-stem-cell-transplantation-from-unmanipulated-haploidentical-and-unrelated-donors-in-acute-leukemia
#1
Simona Piemontese, F Ciceri, M Labopin, W Arcese, S Kyrcz-Krzemien, S Santarone, H Huang, D Beelen, N C Gorin, C Craddock, Z Gulbas, A Bacigalupo, M Mohty, A Nagler
BACKGROUND: In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission...
January 19, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28100265/allogeneic-stem-cell-transplantation-in-adult-patients-with-acute-myeloid-leukaemia-and-17p-abnormalities-in-first-complete-remission-a-study-from-the-acute-leukemia-working-party-alwp-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#2
Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub-Agha, Didier Blaise, Norbert Ifrah, Gérard Socié, Tobias Gedde-Dhal, Nicolaas Schaap, Jan J Cornelissen, Stéphane Vigouroux, Jaime Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, Arnon Nagler
BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected...
January 18, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28092357/risk-of-sinusoidal-obstruction-syndrome-in-allogeneic-stem-cell-transplantation-after-prior-gemtuzumab-ozogamicin-treatment-a-retrospective-study-from-the-acute-leukemia-working-party-of-the-ebmt
#3
G Battipaglia, M Labopin, A Candoni, R Fanin, J El Cheikh, D Blaise, M Michallet, A Ruggeri, N Contentin, J M Ribera, M Stadler, J Sierra, P A von dem Borne, A Bloor, G Socié, A Nagler, M Mohty
Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of 146 adults, with a median age of 50 years, previously receiving GO. SOS prophylaxis was used in 69 patients (heparin n=57, ursodeoxycholic acid n=8, defibrotide n=4). Cumulative incidence (CI) of SOS was 8% (n=11), with death in 3 patients. Median interval between last GO dose and HSCT was 130 days. Overall survival (OS) and SOS incidence did not differ for patients receiving GO ⩽3...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28052366/impact-of-fab-classification-on-predicting-outcome-in-acute-myeloid-leukemia-not-otherwise-specified-patients-undergoing-allogeneic-stem-cell-transplantation-in-cr1-an-analysis-of-1690-patients-from-the-acute-leukemia-working-party-of-ebmt
#4
Jonathan Canaani, Eric Beohou, Myriam Labopin, Gerard Socié, Anne Huynh, Liisa Volin, Jan Cornelissen, Noel Milpied, Tobias Gedde-Dahl, Eric Deconinck, Nathalie Fegueux, Didier Blaise, Mohamad Mohty, Arnon Nagler
The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom NPM1 status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28007754/myeloablative-versus-reduced-intensity-allogeneic-stem-cell-transplantation-for-relapsed-refractory-hodgkin-s-lymphoma-in-recent-years-a-retrospective-analysis-of-the-lymphoma-working-party-of-the-european-group-for-blood-and-marrow-transplantation
#5
S Genadieva-Stavrik, A Boumendil, P Dreger, K Peggs, J Briones, P Corradini, A Bacigalupo, G Socié, F Bonifazi, H Finel, A Velardi, M Potter, B Bruno, L Castagna, R Malladi, N Russell, A Sureda
BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249 RIC) with relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT Database were included in the study. RESULTS: With a median follow-up for alive patients of 56 (26-73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC...
December 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27992075/management-of-veno-occlusive-disease-the-multi-disciplinary-approach-to-care
#6
REVIEW
Elisabeth Wallhult, Michelle Kenyon, Sarah Liptrott, Arno Mank, Mairéad Ní Chonghaile, Aleksandra Babic, Jacobine Bijkerk, Caroline Bompoint, Selim Corbacioglu, Roel de Weijer, Claudia Fink, Sarah Marktel, Vivek Soni, Sarah Sprenger, Eugenia Trigoso Arjona, Mohamad Mohty
Although it is considered a relatively rare disorder, veno-occlusive disease (VOD) is one of the main causes of overall, non-relapse mortality associated with haematopoietic stem cell transplantation (HSCT). This article, based on the consensus opinion of haemato-oncology nurses, haemato-oncologists, and pharmacists from both adult and paediatric services at the VOD International Multi-Disciplinary Advisory Board at the European Society for Blood and Marrow Transplantation (EBMT) meeting, Istanbul, 2015, aims to explore the multi-disciplinary approach to care for the management of VOD, with an emphasis on current challenges in this area...
December 19, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27916512/impact-of-conditioning-regimen-on-outcomes-for-children-with-acute-myeloid-leukemia-undergoing-transplantation-in-first-complete-remission-an-analysis-on-behalf-of-the-pediatric-disease-working-party-of-the-european-group-for-blood-and-marrow-transplantation
#7
Giovanna Lucchini, Myriam Labopin, Eric Beohou, Arnauld Dalissier, Jean Hughes Dalle, Jacqueline Cornish, Marco Zecca, Sujith Samarasinghe, Brenda Gibson, Franco Locatelli, Yves Bertrand, Fawzi Abdel-Rahman, Gerald Socie, Mikael Sundin, Arjan Lankester, Peter Sedlacek, Rose Marie Hamladji, Carsten Heilmann, Boris Afanasyev, Rachel Hough, Cristina Peters, Peter Bader, Paul Veys
Hematopoietic stem cell transplantation (HSCT) represents the cornerstone of treatment in pediatric high-risk and relapsed acute myeloid leukemia (AML). The aim of the present study was to compare outcomes of pediatric patients with AML undergoing HSCT using 3 different conditioning regimens: total body irradiation (TBI) and cyclophosphamide (Cy); busulfan (Bu) and Cy; or Bu, Cy, and melphalan (Mel). In this retrospective study, registry data for patients > 2 and <18 years age undergoing matched allogeneic HSCT for AML in first complete remission (CR1) in 204 European Group for Blood and Marrow Transplantation centers between 2000 and 2010 were analyzed...
December 1, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27906458/autologous-stem-cell-transplantation-for-adult-acute-myelocytic-leukemia-in-first-remission-better-outcomes-after-busulfan-and-melphalan-compared-with-busulfan-and-cyclophosphamide-a-retrospective-study-from-the-acute-leukemia-working-party-of-the-european
#8
Norbert-Claude Gorin, Myriam Labopin, Tomasz Czerw, Thomas Pabst, Didier Blaise, Pierre-Yves Dumas, Damir Nemet, William Arcese, Silvia Maria Trisolini, Depei Wu, Anne Huynh, Tsila Zuckerman, Ellen Meijer, Seckin Cagirgan, Jan Cornelissen, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
BACKGROUND: Autologous stem cell transplantation (ASCT) for adult acute myelogenous leukemia (AML) is a valid therapeutic option for patients with good-risk and intermediate-risk disease. The authors used the registry of the European Society for Blood and Marrow Transplantation to compare combined busulfan and melphalan (BUMEL) with combined busulfan and cyclophosphamide (BUCY) before transplantation. METHODS: From 2005 to 2013, 853 patients with available cytogenetics underwent ASCT in first remission, including 257 after receiving BUMEL and 596 after receiving BUCY...
December 1, 2016: Cancer
https://www.readbyqxmd.com/read/27892949/the-ebmt-eln-working-group-recommendations-on-the-prophylaxis-and-treatment-of-gvhd-a-change-control-analysis
#9
T Ruutu, A Gratwohl, D Niederwieser, T de Witte, S van der Werf, A van Biezen, M Mohty, N Kröger, A Rambaldi, E McGrath, A Sureda, G Basak, H Greinix, R F Duarte
In 2013, recommendations for a standardized practice in the prophylaxis and treatment of GvHD were adopted and published by the European Society for Blood and Marrow Transplantation and the European LeukemiaNet. One year later, all 341 European Society for Blood and Marrow Transplantation centres performing allogeneic haematopoietic stem cell transplantation were contacted for a change-control analysis and asked to fill in a questionnaire; 111 centres (33%) responded. Of these, 83% had been aware of the recommendations...
November 28, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27879990/sequential-chemotherapy-followed-by-reduced-intensity-conditioning-and-allogeneic-haematopoietic-stem-cell-transplantation-in-adult-patients-with-relapse-or-refractory-acute-myeloid-leukaemia-a-survey-from-the-acute-leukaemia-working-party-of-ebmt
#10
Olle Ringdén, Myriam Labopin, Christoph Schmid, Behnam Sadeghi, Emmanuelle Polge, Johanna Tischer, Arnold Ganser, Mauricette Michallet, Lothar Kanz, Rainer Schwerdtfeger, Arnon Nagler, Mohamad Mohty
This study analysed the outcome of 267 patients with relapse/refractory acute myeloid leukaemia (AML) who received sequential chemotherapy including fludarabine, cytarabine and amsacrine followed by reduced-intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). The transplants in 77 patients were from matched sibling donors (MSDs) and those in 190 patients were from matched unrelated donors. Most patients (94·3%) were given anti-T-cell antibodies. The incidence of acute graft-versus-host disease (GVHD) of grades II-IV was 32·1% and that of chronic GVHD was 30·2%...
November 23, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27870355/impact-of-genomic-risk-factors-on-survival-after-haematopoietic-stem-cell-transplantation-for-patients-with-acute-leukaemia
#11
K F Pearce, Y Balavarca, J Norden, G Jackson, E Holler, R Dressel, H Greinix, A Toubert, E Gluckman, I Hromadnikova, P Sedlacek, D Wolff, U Holtick, H Bickeböller, A M Dickinson
The EBMT risk score is an established tool successfully used in the prognosis of survival post-HSCT and is applicable for a range of haematological disorders. One of its main advantages is that score generation involves summation of clinical parameters that are available pretransplant. However, the EBMT risk score is recognized as not being optimal. Previous analyses, involving patients with various diagnoses, have shown that non-HLA gene polymorphisms influence outcome after allogeneic HSCT. This study is novel as it focuses only on patients having acute leukaemia (N = 458) and attempts to demonstrate how non-HLA gene polymorphisms can be added to the EBMT risk score in a Cox regression model to improve prognostic ability for overall survival...
December 2016: International Journal of Immunogenetics
https://www.readbyqxmd.com/read/27847301/hematopoietic-stem-cell-transplant-in-patients-with-activated-pi3k-delta-syndrome
#12
Zohreh Nademi, Mary A Slatter, Christopher C Dvorak, Benedicte Neven, Alain Fischer, Felipe Suarez, Claire Booth, Kanchan Rao, Alexandra Laberko, Julia Rodina, Yves Bertrand, Sylwia Kołtan, Robert Dębski, Terence Flood, Mario Abinun, Andrew R Gennery, Sophie Hambleton, Stephan Ehl, Andrew J Cant
No abstract text is available yet for this article.
November 12, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27819688/allogeneic-haematopoietic-stem-cell-transplant-in-patients-with-lower-risk-myelodysplastic-syndrome-a-retrospective-analysis-on-behalf-of-the-chronic-malignancy-working-party-of-the-ebmt
#13
M Robin, R Porcher, W Zinke-Cerwenka, A van Biezen, L Volin, G Mufti, C Craddock, J Finke, C Richard, J Passweg, A Peniket, J Maertens, G Sucak, T Gedde-Dahl, A Vitek, A Nagler, D Blaise, D Beelen, N Maillard, R Schwerdtfeger, T de Witte, N Kroger
We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation) database who were transplanted for International Prognostic Scoring System (IPSS) low or intermediate-1 disease. The majority of these patients (76%) were reclassified as intermediate or higher risk according to R-IPSS. The 3-year overall survival (OS) and PFS were 58% and 54%, respectively. In a multivariate analysis, adverse risk factors for PFS were marrow blast percentage (hazard ratio (HR): 1...
November 7, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27819687/impact-of-drug-development-on-the-use-of-stem-cell-transplantation-a-report-by-the-european-society-for-blood-and-marrow-transplantation-ebmt
#14
J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro, P Dreger, R F Duarte, C Dufour, J Kuball, D Farge-Bancel, A Gennery, N Kröger, F Lanza, A Nagler, A Sureda, M Mohty
Hematopoietic stem cell transplantation (HSCT) is used with increasing frequency in Europe with 40 000 transplants reported in 2014. Transplant-related mortality remains high in allogeneic HSCT (10-20%); high-dose chemotherapy is toxic and demanding for patients. Drug development is accelerating and with limited toxicity of some targeted drugs may replace HSCT, whereas others may function as a 'bridge to transplant'. We analyzed HSCT reported to the activity survey for selected diseases in which major advances in drug development have been made...
November 7, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27816650/sequential-intensified-conditioning-regimen-allogeneic-hematopoietic-stem-cell-transplantation-in-adult-patients-with-intermediate-or-high-risk-acute-myeloid-leukemia-in-complete-remission-a-study-from-the-acute-leukemia-working-party-of-the-european-group
#15
Florent Malard, Myriam Labopin, Gernot Stuhler, Jörg Bittenbring, Arnold Ganser, Johanna Tischer, Mauricette Michallet, Nicolaus Kröger, Christoph Schmid, Anne Huynh, Michael Hallek, Bipin N Savani, Mohamad Mohty, Arnon Nagler
Post-transplant relapse is the leading cause of treatment failure in acute myeloid leukemia (AML) patients after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (allo-HSCT). To improve their outcome, we evaluated the outcome of a sequential intermediate-intensity conditioning regimen combining fludarabine, cytosine arabinoside, amsacrine, cyclophosphamide, and either total body irradiation or busulfan (FLAMSA) in patients with intermediate or high-risk AML in first or second complete remission (CR)...
February 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27777140/unrelated-cord-blood-transplantation-for-acute-leukemia-diagnosed-in-the-first-year-of-life-outcomes-and-risk-factor-analysis
#16
Annalisa Ruggeri, Fernanda Volt, Franco Locatelli, Gerard Michel, Cristina Diaz de Heredia, Manuel Abecasis, Marco Zecca, Ajay Vora, Karima Yakouben, Tracey A O'Brien, Stefano Giardino, Jacqueline Cornish, Vanderson Rocha, Christina Peters, Peter Bader, Eliane Gluckman, Jean Hugues Dalle
Infant acute leukemia still has a poor prognosis, and allogeneic hematopoietic stem cell transplantation is indicated in selected patients. Umbilical cord blood (UCB) is an attractive cell source for this population because of the low risk of chronic graft-versus-host disease (GVHD), the strong graft-versus-leukemia effect, and prompt donor availability. This retrospective, registry-based study reported UCB transplantation (UCBT) outcomes in 252 children with acute lymphoblastic leukemia (ALL; n = 157) or acute myelogenous leukemia (AML; n = 95) diagnosed before 1 year of age who received a single-unit UCBT after myeloablative conditioning between 1996 and 2012 in European Society for Blood and Marrow Transplantation centers...
January 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27720995/allogeneic-stem-cell-transplantation-for-patients-age-%C3%A2-70-years-with-myelodysplastic-syndrome-a-retrospective-study-of-the-mds-subcommittee-of-the-chronic-malignancies-working-party-of-the-ebmt
#17
Silke Heidenreich, Dimitris Ziagkos, Liesbeth C de Wreede, Anja van Biezen, Jürgen Finke, Uwe Platzbecker, Dietger Niederwieser, Hermann Einsele, Wolfgang Bethge, Michael Schleuning, Dietrich W Beelen, Johanna Tischer, Arnon Nagler, Bertram Glass, Johan Maertens, Lucrecia Yáñez, Yves Beguin, Heinz Sill, Christof Scheid, Matthias Stelljes, Arnold Ganser, Pierre Zachée, Dominik Selleslag, Theo de Witte, Marie Robin, Nicolaus Kröger
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52)...
January 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27673280/thiotepa-based-conditioning-for-allogeneic-stem-cell-transplantation-in-acute-lymphoblastic-leukemia-a-survey-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation
#18
Sandra Eder, Eric Beohou, Myriam Labopin, Jaime Sanz, Jürgen Finke, William Arcese, Reuven Or, Francesca Bonifazi, Mahmoud Aljurf, Gerard Socié, Jakob Passweg, Sebastian Giebel, Mohamad Mohty, Arnon Nagler
In this study, we analyzed a thiotepa-based conditioning regimen for allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia, using the EBMT database. A total of 323 patients were identified. The median age was 43 years. Disease status at transplant was first complete remission (CR1) in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. This was performed from a HLA-matched sibling (49.8%) or a matched-unrelated donor (51...
January 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/27658761/a-prospective-study-on-the-natural-history-of-patients-with-profound-combined-immunodeficiency-p-cid-an-interim-analysis
#19
Carsten Speckmann, Sam Doerken, Alessandro Aiuti, Michael H Albert, Waleed Al-Herz, Luis M Allende, Allessia Scarselli, Tadej Avcin, Ruy Perez-Becker, Caterina Cancrini, Andrew Cant, Silvia Di Cesare, Andrea Finocchi, Alain Fischer, H Bobby Gaspar, Sujal Ghosh, Andrew Gennery, Kimberly Gilmour, Luis I González-Granado, Monica Martinez-Gallo, Sophie Hambleton, Fabian Hauck, Manfred Hoenig, Despina Moshous, Benedicte Neven, Tim Niehues, Luigi Notarangelo, Capucine Picard, Nikolaus Rieber, Ansgar Schulz, Klaus Schwarz, Markus G Seidel, Pere Soler-Palacin, Polina Stepensky, Brigitte Strahm, Thomas Vraetz, Klaus Warnatz, Christine Winterhalter, Austen Worth, Sebastian Fuchs, Annette Uhlmann, Stephan Ehl
BACKGROUND: Absent T cell immunity resulting in life-threatening infections provides a clear rationale for hematopoetic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency (SCID). Combined immunodeficiencies (CID) and "atypical" SCID show reduced, not absent T-cell immunity. If associated with infections or autoimmunity, they represent profound CID (P-CID), for which outcome data are insufficient for unambiguous early transplant decisions. OBJECTIVES: We recruit non-transplanted P-CID patients aged 1-16 years to compare natural histories of severity-matched patients with/without subsequent transplantation and to determine whether immunological and/or clinical parameters may be predictive for outcome...
September 19, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27650829/prognostic-pre-transplant-factors-in-myelodysplastic-syndromes-primarily-treated-by-high-dose-allogeneic-hematopoietic-stem-cell-transplantation-a-retrospective-study-of-the-mds-subcommittee-of-the-cmwp-of-the-ebmt
#20
E M P Cremers, A van Biezen, L C de Wreede, M Scholten, A Vitek, J Finke, U Platzbecker, D Beelen, R Schwerdtfeger, L Volin, N Harhalakis, N Blijlevens, A Nagler, N Kröger, T de Witte
Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS). However, patient cohorts are often heterogeneous by disease stage and treatment modalities, which complicates interpretation of the results. This study aimed to obtain a homogeneous patient cohort by including only de novo MDS patients who received upfront allogeneic SCT after standard high dose myelo-ablative conditioning. The effect of pre-transplant factors such as age, disease stage, transfusions, iron parameters and comorbidity on overall survival (OS), non-relapse mortality (NRM), and relapse incidence (RI) was evaluated in 201 patients...
December 2016: Annals of Hematology
keyword
keyword
115198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"